Clinical study of gemcitabine combined with S-1 in the treatment of advanced biliary tract cancer
10.3760/cma.j.issn.1008-6706.2019.14.005
- VernacularTitle: 吉西他滨联合替吉奥一线治疗晚期胆道系统肿瘤的临床研究
- Author:
Xiaoqian WANG
1
;
Liying LIU
;
Dedong WU
Author Information
1. Department of Oncology, the First People's Hospital of Zhengzhou, Zhengzhou, He′nan 450052, China
- Publication Type:Journal Article
- Keywords:
Digestive system neoplasms;
Biliary tract neoplasms;
Bile duct neoplasms;
Drug therapy;
Antineoplastic combined chemotherapy protocols;
Adverse effects;
Gemcitabine;
Tegafur
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(14):1683-1685
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the recent efficacy and safety of gemcitabine combined with S-1 in the treatment of advanced biliary tract cancer.
Methods:From August 2014 to May 2017, 27 patients with advanced biliary tract cancer confirmed by pathology in the First People's Hospital of Zhengzhou received gemcitabine(1 000mg/m2, day 1 and 8) and S-1(80mg/m2, day 1-14) every three weeks.The recent efficacy and toxicities were observed after two cycles of chemotherapy.
Results:All of the 27 patients were evaluated, 1 patient(3.7%) achieved CR, 6 patients(22.2%) with PR, 12 patients(44.4%) with SD, 8 patients(29.6%) with PD.The total response rate was 25.9%(7/27), the disease control rate was 70.4%(19/27). The main toxicities were gastrointestinal reactions and myelosuppression, no chemotherapy-related death was observed.
Conclusion:Gemcitabine combined with S-1 in the treatment of advanced biliary tract cancer is safe and effect.
